Adma Biologics (ADMA) Current Deferred Revenue (2013 - 2025)
Adma Biologics (ADMA) reported Current Deferred Revenue of $143000.0 for Q2 2025, down 87.35% on a YoY basis from $1.1 million in Q2 2024, and little changed quarter-over-quarter from $143000.0 in Q1 2025.
Adma Biologics (ADMA) Current Deferred Revenue (2013 - 2025) Analysis & Trends
Adma Biologics has reported Current Deferred Revenue for 13 years, with the latest figure at $143000.0 in Q2 2025.
- For the quarter ending Q2 2025, Current Deferred Revenue fell 87.35% year-over-year to $143000.0; the trailing twelve-month figure through Jun 2025 stood at $143000.0 (down 87.35% YoY), and the FY2024 full-year result was $143000.0, down 21.43% from the prior year.
- Current Deferred Revenue for Q2 2025 stood at $143000.0, roughly flat from $143000.0 in the prior quarter.
- The five-year high for Current Deferred Revenue was $1.1 million in Q2 2024, with the low at $142834.0 in Q1 2021.
- Historically, Current Deferred Revenue has averaged $254074.4 across 5 years, with a median of $142834.0 in 2021.
- Annual changes were most pronounced in 2024 — Current Deferred Revenue surged 691.13% — and 2025, when it plunged 87.35%.
- Adma Biologics' Current Deferred Revenue stood at $142834.0 in 2021, then gained by 0.12% to $143000.0 in 2022, then climbed by 27.27% to $182000.0 in 2023, then slipped by 21.43% to $143000.0 in 2024, then changed by 0.0% to $143000.0 in 2025.
- The last three Current Deferred Revenue figures came in at $143000.0 (Q2 2025), $143000.0 (Q1 2025), and $143000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Adma Biologics | 1.98 Bn | 1.89 Bn | 88.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 143,000.00 |
| Mar 31, 2025 | 143,000.00 |
| Dec 31, 2024 | 143,000.00 |
| Sep 30, 2024 | 143,000.00 |
| Jun 30, 2024 | 1.13 Mn |
| Mar 31, 2024 | 1.12 Mn |
| Dec 31, 2023 | 182,000.00 |
| Sep 30, 2023 | 142,834.00 |
| Jun 30, 2023 | 142,834.00 |
| Mar 31, 2023 | 142,834.00 |
| Dec 31, 2022 | 143,000.00 |
| Sep 30, 2022 | 142,834.00 |
| Jun 30, 2022 | 142,834.00 |
| Mar 31, 2022 | 142,834.00 |
| Dec 31, 2021 | 142,834.00 |
| Sep 30, 2021 | 142,834.00 |
| Jun 30, 2021 | 142,834.00 |
| Mar 31, 2021 | 142,834.00 |
| Dec 31, 2020 | 142,834.00 |
| Sep 30, 2020 | 142,834.00 |